Resection Of Prostate For Treatment Research Articles

Role of Different Types of Anti Androgen in Reduction of Perioperative Bleeding In Transurethral Resection of Prostate for Treatment of Large Size Prostate

Background : Perioperative bleeding and excessive fluid absorption are inherent complications of TURP. These complications are related directly to the size although transurethral prostatectomy is still considered the gold standard for operative treatment of benign prostatic hyperplasia, it is not a procedure without morbidity. the prostate is an androgen dependent organ. This study was aimed to compare the impact of use cyproteron acetate versus dutasteride in reduction of perioperative bleeding in transurethral resection of prostate for treatment of large size prostate. Patient & Methods: This a randomized controlled trial study was conducted for 6 months on 63 patients, from December 2018 to May 2019, who were admitted to urology department in zagazig university patients were randomized through a computer randomization into three equal groups. Results: The current study revealed that Control group was statistically significant decrease of HB and HCT post operative than other two groups and significant less operative time in patients received pre operative medication than control group with consequence decrease need for transfusion as well as less hospital stay .Conclusion: The pre operative use of anti androgen drugs (CPA & dutasteride) in TURP of large size prostate is well tolerated in the properly selected patients and it can help in decreasing the perioperative bleeding and fluid absorption during this surgery also ,operative time ,hospital stay.

Safety and Efficacy of Thulium Laser Prostatectomy Versus Transurethral Resection of Prostate for Treatment of Benign Prostate Hyperplasia: A Meta‐Analysis

The aim of the present study was to objectively evaluate the safety and efficacy of Thulium laser prostatectmy (TmLRP) versus transurethral resection of prostate (TURP) in treating benign prostate hyperplasia (BPH). Online databases such as Cochrane Library, PubMed, Embase, and Chinese biomedicine literature database were searched by randomized control trial (RCT), quasi-randomized control trial (Q-RCT) and case control study (CCSs) about TmLRP versus TURP for the treatment of BPH. After study selection, assessment and data extraction conducted, Meta-analyses were performed by using the RevMan 5.2 software. Six studies involving 640 patients were included and the results of follow-up time was 1 year. The results of meta-analyses showed that: (i) safety indicators: compared with TURP, TmLRP was associated with less decrease of serum sodium salt, less blood transfusion, shorter catheterization time hospital time and more operation time. No differences were noted in the TUR syndrome, recatheterization rate, transitory urge incontinence, stress incontinence urethral stricture and retrograde ejaculation. (ii) Efficacy indicators (International Prostate Symptom Score [IPSS], post-void residual [PVR], Qmax, quality of life [QoL]): Compared with the baseline, significant improvement in IPSS, QoL, Qmax and PVR were obvious improvement before and after surgery in both groups. There were statistical differences in IPSS at 12 months, QoL at 1, 6 months and Qmax 1, 6 months between the two groups. TmLRP is a safe and effective procedure for treatment of benign prostatic hyperplasia. Compared with TURP, TmLRP was not only associated with less decrease of serum sodium salt, less blood transfusion, shorter catheterization time and hospital time, but also may be superior to TURP in efficacy.

A Prospective Study on the Effect of Photoselective Vaporization of Prostate by 120-W High-Performance System Laser on Sexual Function

Photoselective vaporization of prostate (PVP) by 120W HPS laser emerged as an efficient, bloodless, and durable first line alternative to transurethral resection of prostate for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE). In this study, we assessed effects of PVP by HPS laser on erectile function. Between January 2012 and February 2014, 143 consecutive patients presenting with LUTS secondary to BPE, who underwent PVP by 120W HPS laser, were prospectively enrolled in the study. Patient's (Group A: International Index of Erectile Function-5 (IIEF-5) ≥19; Group B: IIEF <19) preoperative, perioperative and follow-up data were recorded. IIEF-5 was used to assess preoperative and postoperative erectile function at 1, 3, 6, and 12 months. Recorded data was analyzed statistically. Preoperative and perioperative data of the two groups were comparable. Significant improvement in IPSS, Qmax, QoL, and post void residual urine at 1, 3, 6 and 12 months were observed in both groups with no significant difference between them. Although IIEF-5 scores declined in both groups postoperatively (Group A: 21.06±1.21 to 19.84±1.55, P=0.43; Group B: 14.67±2.05 to 12.79±1.42, P=0.53), it was not statistically significant in either group. No significant difference was noted in IIEF-5 score between patients with or without indwelling catheter in either of the two groups. In patients undergoing PVP by 120W HPS laser for LUTS secondary to BPE, no significant effect was observed in sexual function at 1 year follow-up.

MP-07.15 Evaluation of Effect of Photoselective Vaporization of Prostate on Sexual Function in a Prospective Study: A Single Centre Experience of 150 Patients

Photoselective vaporization of prostate has emerged as a minimally invasive alternative to transurethral resection of prostate for treatment of benign prostate enlargement with lower urinary tract symptoms. Very few prospective studies have addressed the effect of PVP on sexual function. We performed this prospective study to assess the short-term effect of PVP on erectile function in patients presenting with BPE and LUTS.

MP-06.02: Transurethral Suspendplasma Resection of Prostate for Treatment of BPH Patients

MP-06.02: Transurethral Suspendplasma Resection of Prostate for Treatment of BPH Patients

Transurethral RollerLoop vapor resection of prostate for treatment of symptomatic benign prostatic hyperplasia: A 2-year follow-up study

We compared the 2-year safety and efficacy of two transurethral resection techniques-transurethral vapor resection of the prostate (TUVRP) and conventional loop transurethral resection of the prostate (TURP)-in the surgical management of benign prostatic hyperplasia. Between August 1997 and September 2002, 441 patients underwent transurethral prostatectomy, either TUVRP (n = 221) or TURP (n = 220). TUVRP was performed using a "RollerLoop" resection loop. All patients were assessed preoperatively by means of International Prostate Symptom Score (IPSS), quality of life (QOL) score, prostate volume, peak urinary flow (Qmax) and post-void residual volume (PVR) measurements and a sexual function questionnaire. Patients were followed up for 3, 6, 12 and 24 months after surgery, and this was followed by a comparison of the incidences of sexual dysfunction, complications and re-treatment. After 2 years of follow-up, no differences were noted between the TUVRP and TURP groups with respect to average IPSS (p = 0.9), QOL scores (p = 0.56), Qmax (p = 0.89) or PVR (p = 0.55), as well as the incidences of bladder neck contracture or urethral stricture (p = 0.34), re-treatment (p = 0.49) or sexual dysfunction (p = 0.57). However, significant reductions in operative time (p = 0.005), decrease in serum hemoglobin levels (p < 0.001), catheterization time (p < 0.001), postoperative hospital stay (p < 0.001) and hospitalization costs (p < 0.001) were observed in the TUVRP group compared to the TURP group. Our results suggest that TUVRP provides equivalent safety and efficacy to TURP during a 2-year follow-up period, in which short-term advantages in perioperative morbidity and cost savings were also demonstrated.

1391: Transurethral Enucleative Resection of Prostate for Treatment of Benign Prostatic Hyperplasia with Bipolar Endoscopic System ( 600 Cases Report)

1391: Transurethral Enucleative Resection of Prostate for Treatment of Benign Prostatic Hyperplasia with Bipolar Endoscopic System ( 600 Cases Report)